Atea Pharmaceuticals (Nasdaq: AVIR) has initiated a first-in-human Phase 1 clinical trial of AT-587, an oral antiviral nucleotide analog being ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE